It sounds like you are saying the program isn't worth much until you see P1 data.
I did my work on that some time ago and this BPMC deal hasn't changed anything on that unless the market prices the cvr differently than what I'm expecting, which would just tweak my numbers.
Anyhow since there aren't any notes to compare there is no point acting like a peacock.